AbbVie Inc. logo

AbbVie Inc. (0QCV)

Market Open
21 Jul, 18:14
LSE LSE
$
146. 95
0
0%
$
323.26B Market Cap
42.2 P/E Ratio
6.2% Div Yield
123,965 Volume
10.28 Eps
$ 146.95
Previous Close
Day Range
146.95 154.06
Year Range
131.22 167.8
Want to track 0QCV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 55 days

Summary

0QCV trading today higher at $146.95, an increase of 0% from yesterday's close, completing a monthly increase of 0% or $146.95. Over the past 12 months, 0QCV stock gained 0%.
0QCV pays dividends to its shareholders, with the most recent payment made on Nov 14, 2025. The next announced payment will be in In 2 months on Feb 17, 2026 for a total of $1.73.
The last earnings report, released on Oct 31, 2025, missed the consensus estimates by -1.68%. On average, the company has fell short of earnings expectations by -0.56%, based on the last three reports. The next scheduled earnings report is due on Jan 29, 2026.
The stock of the company had never split.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NYSE (USD).

0QCV Chart

How Strong Is AbbVie's Immunology Franchise After Humira's LOE?

How Strong Is AbbVie's Immunology Franchise After Humira's LOE?

ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.

Zacks | 19 hours ago
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Seekingalpha | 1 day ago
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 1 day ago

AbbVie Inc. (0QCV) FAQ

What is the stock price today?

The current price is $146.95.

On which exchange is it traded?

AbbVie Inc. is listed on NYSE.

What is its stock symbol?

The ticker symbol is 0QCV.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 6.2%.

What is its market cap?

As of today, the market cap is 323.26B.

When is the next earnings date?

The next earnings report will release on Jan 29, 2026.

Has AbbVie Inc. ever had a stock split?

No, there has never been a stock split.

AbbVie Inc. Profile

- Industry
- Sector
Robert A. Michael CPA CEO
LSE Exchange
US00287Y1091 ISIN
US Country
55,000 Employees
16 Jan 2026 Last Dividend
- Last Split
2 Jan 2013 IPO Date

Overview

AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.

Products and Services

  • Humira: A therapeutic injection for various autoimmune diseases, including intestinal Behçet's disease and pyoderma gangrenosum.
  • Skyrizi: Prescribed for patients with moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease, focusing on improving skin health.
  • Rinvoq: Targets multiple conditions such as rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and several gastrointestinal diseases.
  • Imbruvica: An oral medication for adults with various blood cancers, marking significant advancements in oncology.
  • Epkinly and Elahere: Treatments tailored for different forms of lymphoma and cancer, showcasing AbbVie's innovations in targeted therapies.
  • Venclexta/Venclyxto: Offers hope for patients battling blood cancers, through a regimen that interferes with cancer cell survival.
  • Aesthetic Products: A range of facial injectables, plastics and regenerative medicine, body contouring, and skincare offerings that cater to aesthetic needs.
  • Botox Therapeutic: Beyond cosmetic applications, this product is utilized for various therapeutic purposes, enhancing patient care.
  • Vraylar: A medication designed to address depressive disorder, contributing to mental health treatment options.
  • Duopa and Duodopa: These formulations provide relief for patients with advanced Parkinson's disease, improving quality of life.
  • Ubrelvy and Qulipta: Target the acute treatment of migraine in adults, including both episodic and chronic forms.
  • Ozurdex: An ocular implant designed to treat eye diseases, emphasizing AbbVie's contribution to ophthalmology.
  • Lumigan/Ganfort and Alphagan/Combigan: Aimed at reducing intraocular pressure in conditions like open-angle glaucoma or ocular hypertension.
  • Restasis: Helps increase tear production, addressing the needs of patients with dry eye disease.
  • Mavyret/Maviret: Administered for the treatment of chronic hepatitis C virus (HCV) infection, representing a breakthrough in HCV treatment.
  • Creon: A pancreatic enzyme therapy essential for patients with pancreatic insufficiency, aiding digestion.
  • Lupron: Utilized for treating advanced prostate cancer, endometriosis, central precocious puberty, and uterine fibroids-related anemia.
  • Linzess/Constella: Offers relief for irritable bowel syndrome with constipation and chronic idiopathic constipation.
  • Synthroid: A synthetic thyroid hormone used to treat hypothyroidism, ensuring thyroid hormone levels are balanced.

Contact Information

Address: 1 North Waukegan Road
Phone: 847 932 7900